Searching News Database: Sobi
HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
HSMN NewsFeed - 15 Oct 2021
Aspaveli(R) (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Aspaveli(R) (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
HSMN NewsFeed - 18 Sep 2020
Orfadin(R) (nitisinone) receives positive opinion from CHMP for treatment of AKU
Orfadin(R) (nitisinone) receives positive opinion from CHMP for treatment of AKU
HSMN NewsFeed - 30 Sep 2019
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
HSMN NewsFeed - 12 Jun 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 22 Aug 2018
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
Sobi(TM) Appoints Anne Marie de Jonge Schuermans as Head of Technical Operations
HSMN NewsFeed - 10 Nov 2017
Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
HSMN NewsFeed - 25 Oct 2017
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
HSMN NewsFeed - 6 Oct 2017
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
HSMN NewsFeed - 30 Jun 2017
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 13 Feb 2013
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
HSMN NewsFeed - 27 Jan 2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
HSMN NewsFeed - 28 Dec 2010
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US